hcn.health Open in urlscan Pro
35.231.43.240  Public Scan

Form analysis
1 forms found in the DOM

https://hcn.health/

<form role="search" id="search-form" action="https://hcn.health/">
  <input type="search" id="search" class="search-field" placeholder="Search" value="" name="s">
  <button type="submit" class="search-submit"><img src="https://hcn.health/wp-content/themes/hcn_2020/assets/dist/images/search-icon.png"></button>
</form>

Text Content

SPECIALTIES

Select category
Internal Medicine Oncology, Medical Family Medicine/General Practice Obstetrics
& Gynecology Hematology Oncology, Surgical Oncology, Radiation Surgery, General
Neurology Psychiatry Cardiology Pediatrics Allergy & Immunology Endocrinology,
Diabetes, Metabolism Pulmonology Rheumatology Emergency Medicine Urology
Dermatology Gastroenterology Geriatrics Radiology Ophthalmology Anesthesiology
Pathology Hospitalist Surgery, Plastic Cardiology, Interventional Medical
Genetics All Specialties Residency Hepatology Pain Medicine Surgery, Neurologic
Surgery, Orthopedic Clinical Pharmacology Nephrology Physical Medicine &
Rehabilitation Surgery, Colon & Rectal Neuromusculoskeletal Medicine & OMM
Otolaryngology


 * Home
 * About HCN
 * Sources
 * Link Central
   * The Clinician’s Nutrition Roundup
   * COVID & Company
   * In the Interest of Public Health
   * Legal Dealings
   * Medical Meetings and Conferences
   * Medicine, Inc.
   * Politics & Medicine
 * Contact Us

Peer-influenced content. Sources you trust. No registration required. This is
HCN.


ESSENTIAL MEDICAL READING

Your Weekly Roundup of the Most-Read News and Clinical References from Your
Peers

JAMA Network

TREATMENT WITH STEREOTACTIC ABLATIVE RADIOTHERAPY FOR UP TO 5 OLIGOMETASTASES IN
PATIENTS WITH CANCER

Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial
The rates of grades 2, 3, 4, and 5 toxic effects were 14.2%, 4.2%, 0%, and 0.3%,
respectively, in this population-based phase 2 nonrandomized clinical trial of
381 patients with oligometastatic or oligoprogressive disease that was designed
to capture toxic effects prospectively as the primary end point.

Oncology, Medical October 7th 2022

Tags: CLINICAL TRIALS RADIOTHERAPY SOLID TUMORS

MedPage Today

HOSPITAL FIRED ALL EMPLOYEES; PROFITING OFF THE POOR; LONG COVID AND ME/CFS

This week’s edition of MedPage Today’s Investigative Roundup highlights some of
the best investigative reporting on healthcare, including the lifechanging
decision by Noble Health in Missouri to suspend all services and furlough 181
employees from Audrain Community Hospital and nearby Callaway Community
Hospital.

All Specialties October 7th 2022

Tags: LEGAL MATTERS MEDICAL MISINFORMATION

Cancer Therapy Advisor

CANCER TREATMENT REGIMENS

Cancer Therapy Advisor provides a variety of resources, including regimens used
to supplement the most recent treatment strategies. Examine all regimens here.

Oncology, Medical October 7th 2022

Tags: BREAST CANCER GASTROESOPHAGEAL CANCER GENITOURINARY CANCER GYNECOLOGICAL
CANCERS HEAD & NECK CANCER (HNC) HEMATOLOGY/ONCOLOGY LUNG CANCER MEDICAL
PRACTICE SKIN CANCER

OBR Oncology

TO SPECIALIZE OR NOT TO SPECIALIZE: CAN COMMUNITY ONCOLOGISTS CONTINUE AS
GENERALISTS?

The experts seem to say “yes,” although the shortage of oncologists and a
growing number of cancer patients will require that oncologists treat a broad
range of cancers is challenging that direction.

Oncology, Medical October 7th 2022

Tags: BUSINESS OF MEDICINE MEDICAL CAREERS MEDICAL COMMENTARY/OPINION

MDCalc

TOP MEDICAL CALCULATORS IN NEUROPSYCHIATRY

The most popular calculators in neuropsychiatry: 5. Antibody Prevalence in
Epilepsy and Encephalopathy (APE2 ) Score4. PECARN Pediatric Head Injury/Trauma
Algorithm3. GAD-7 (General Anxiety Disorder-7)2. Ideal Body Weight and Adjusted
Body Weight1. PHQ-9 (Patient Health Questionnaire-9)

Neurology October 7th 2022

Tags: MEDICAL CALCULATOR

Psychiatry Advisor

DEXTROMETHORPHAN-BUPROPION EFFECTIVE FOR COMORBID ANXIETY, MAJOR DEPRESSIVE
DISORDER

Data from the open label Evaluation of NMDA Modulation for Depressive Episodes
(EVOLVE) study presented at Psych Congress 2022 showed a significant decrease in
HAM-A scores at 1 week, with further decreases in scores observed through 12
months.

Psychiatry October 7th 2022

Tags: CLINICAL STUDY DEPRESSION
1 2 … 165 166 >>

TOPICS

Select topic All Specialties Allergy & Immunology Anesthesiology Cardiology
Cardiology, Interventional Clinical Pharmacology Dermatology Emergency Medicine
Endocrinology, Diabetes, Metabolism Family Medicine/General Practice
Gastroenterology Geriatrics Hematology Hepatology Hospitalist Internal Medicine
Medical Genetics Nephrology Neurology Neuromusculoskeletal Medicine & OMM
Obstetrics & Gynecology Oncology, Medical Oncology, Radiation Oncology, Surgical
Ophthalmology Otolaryngology Pain Medicine Pathology Pediatrics Physical
Medicine & Rehabilitation Psychiatry Pulmonology Radiology Residency
Rheumatology Surgery, Colon & Rectal Surgery, General Surgery, Neurologic
Surgery, Orthopedic Surgery, Plastic Uncategorized Urology

SOURCES

ACP INTERNIST

AMERICAN ACADEMY OF DERMATOLOGY

ANNALS OF INTERNAL MEDICINE

ASH CLINICAL NEWS

BLOOD

BLOOD ADVANCES

BRITISH MEDICAL JOURNAL

CANCER THERAPY ADVISOR

CLEVELAND CLINIC JOURNAL OF MEDICINE

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY

GOODRX HEALTH

GUIDELINE CENTRAL

HEALIO

HEALTHGRADES FOR PROFESSIONALS

JAMA NETWORK

JOURNAL OF CLINICAL ONCOLOGY

KEVINMD.COM

MEDPAGE TODAY

MONTHLY PRESCRIBING REFERENCE (MPR)

PEDIATRICS (AAP)

 * © Healthcare Communications Network
 * Medical Meetings and Conferences
 * Privacy Policy
 * Do Not Sell My Personal Information